Vascular brachytherapy for patients with drug-eluting stent restenosis.

BACKGROUND The rate of drug-eluting stent (DES) in-stent restenosis (ISR) exceeds 10% in complex subsets of patients and lesions. The optimal management of DES ISR remains undetermined. Vascular brachytherapy (VBT) is proven to be effective for the treatment of bare metal stent ISR but its outcome for DES ISR has not been established. METHODS Ninety-nine consecutive patients who presented with ISR following DES implantation in 122 lesions were subjected to conventional percutaneous coronary intervention with adjunct VBT using either beta radiation (Beta Rail in 74 patients [82.2%] and the Galileo system in 13 patients [14.4%]) or gamma radiation (Checkmate system in 3 patients [3.3%]). Patients were followed clinically for major adverse cardiac events (MACE) during 1-year follow-up. RESULTS A high proportion of patients in this cohort presented with complex ISR; 31.1% had recurrences of ISR to the same site, 55% had diffuse or proliferate pattern of restenosis, and 23 lesions (18.9%) were located in a saphenous vein graft. Procedural success and uneventful in-hospital course were documented in all patients post VBT. At 12 months' follow-up, the target lesion revascularization (TLR) rate was 11% and the overall MACE rate was 26%. Patients with multiple episodes of ISR to the same site had a TLR of 16% and MACE rate of 35.5%. CONCLUSIONS VBT for the treatment of DES ISR was found to be effective and safe and should be considered for the treatment of DES ISR, in particular in complex patients with multiple recurrences.

[1]  G. Stone,et al.  Clinical outcomes after heterogeneous overlap stenting with drug-eluting stents and bare-metal stents for de novo coronary artery narrowings. , 2011, The American journal of cardiology.

[2]  G. Stone,et al.  Two-year clinical outcomes after paclitaxel-eluting stent or brachytherapy treatment for bare metal stent restenosis: the TAXUS V ISR trial. , 2008, European heart journal.

[3]  D. Holmes,et al.  Cost-effectiveness of sirolimus-eluting stents compared with vascular brachytherapy for the treatment of in-stent restenosis. , 2007, American heart journal.

[4]  Patrick W Serruys,et al.  Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL trial. , 2007, Journal of the American College of Cardiology.

[5]  W. Weintraub The pathophysiology and burden of restenosis. , 2007, The American journal of cardiology.

[6]  Seung‐Jung Park,et al.  Comparison of six-month angiographic and three-year outcomes after sirolimus-eluting stent implantation versus brachytherapy for bare metal in-stent restenosis. , 2007, The American journal of cardiology.

[7]  K. Kent,et al.  Treatment of drug‐eluting stent restenosis with the same versus different drug‐eluting stent , 2007, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[8]  G. Percoco,et al.  Long-Term Safety and Efficacy of Drug-Eluting Stents: Two-Year Results of the REAL (REgistro AngiopLastiche dell’Emilia Romagna) Multicenter Registry , 2007, Circulation.

[9]  A. Colombo,et al.  Comparable clinical outcomes with paclitaxel- and sirolimus-eluting stents in unrestricted contemporary practice. , 2007, Journal of the American College of Cardiology.

[10]  R. Virmani,et al.  Pathological Correlates of Late Drug-Eluting Stent Thrombosis: Strut Coverage as a Marker of Endothelialization , 2007, Circulation.

[11]  A. Colombo,et al.  Repeated drug-eluting stent implantation for drug-eluting stent restenosis: the same or a different stent. , 2007, American heart journal.

[12]  P. Teirstein,et al.  Intracoronary radiation therapy for multi‐drug resistant in‐stent restenosis: Initial clinical experience , 2007, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[13]  K. Kent,et al.  Intravascular brachytherapy versus drug-eluting stents for the treatment of patients with drug-eluting stent restenosis. , 2006, The American journal of cardiology.

[14]  Raghava R. Gollapudi,et al.  Early- and medium-term outcomes after paclitaxel-eluting stent implantation for sirolimus-eluting stent failure. , 2006, The American journal of cardiology.

[15]  G. Stone,et al.  Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the TAXUS V ISR randomized trial. , 2006, JAMA.

[16]  P. Teirstein,et al.  Sirolimus-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the SISR randomized trial. , 2006, JAMA.

[17]  Kurt Ulm,et al.  Sirolimus-eluting stents vs paclitaxel-eluting stents in patients with coronary artery disease: meta-analysis of randomized trials. , 2005, JAMA.

[18]  D. Simon,et al.  Molecular Basis of Restenosis and Drug-Eluting Stents , 2005, Circulation.

[19]  G. Stone,et al.  Intravascular ultrasound assessment of lesions with target vessel failure after sirolimus-eluting stent implantation. , 2005, The American journal of cardiology.

[20]  A. Kastrati,et al.  Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. , 2005, JAMA.

[21]  Giuseppe Musumeci,et al.  Localized Hypersensitivity and Late Coronary Thrombosis Secondary to a Sirolimus-Eluting Stent: Should We Be Cautious? , 2004, Circulation.

[22]  C. Macaya,et al.  A randomized comparison of repeat stenting with balloon angioplasty in patients with in-stent restenosis. , 2003, Journal of the American College of Cardiology.

[23]  R. Virmani,et al.  Time Course of Stent Endothelialization After Intravascular Radiation Therapy in Rabbit Iliac Arteries , 2003, Circulation.

[24]  Antonio Colombo,et al.  Selection of coronary stents. , 2002, Journal of the American College of Cardiology.

[25]  A. Pichard,et al.  Twelve Versus Six Months of Clopidogrel to Reduce Major Cardiac Events in Patients Undergoing &ggr;-Radiation Therapy for In-Stent Restenosis: Washington Radiation for In-Stent restenosis Trial (WRIST) 12 Versus WRIST PLUS , 2002, Circulation.

[26]  A. Yeung,et al.  Use of localised intracoronary β radiation in treatment of in-stent restenosis: the INHIBIT randomised controlled trial , 2002, The Lancet.

[27]  K. Kent,et al.  Three-year follow-up after intracoronary gamma radiation therapy for in-stent restenosis: Original WRIST , 2001 .

[28]  P. Teirstein,et al.  Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenosis after stenting. , 2001, The New England journal of medicine.

[29]  G. Stone,et al.  Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. , 1999, Circulation.

[30]  P. Serruys,et al.  Late coronary occlusion after intracoronary brachytherapy. , 1999, Circulation.

[31]  E. Topol,et al.  Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. , 1996, Circulation.

[32]  M. Leon,et al.  In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. , 1998, Journal of the American College of Cardiology.